ZL006 |
Catalog No.GC30818
One-Click Copy Product Info
|
ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1181226-02-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
ZL006 presents little cytotoxicity, and a growth inhibition of BCECs is not found at low concentration of 0.001, 0.01, 0.1, 1 and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is significantly enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs[1]. ZL006 does not inhibit the nNOS-PDZ/PSD-95-PDZ interaction, or perturb the nNOS β-finger[2].
Compared with P-LPs/ZL006 and free ZL006, T7-P-LPs/ZL006 exhibits a significant increase of drug accumulation in the brain tissue due to its better brain targeting delivery. Compared with free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 exhibit a significant decrease of drug accumulation in the liver and kidney[1].
[1]. Wang Z, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015 Jul 29;5:12651. [2]. Bach A, et al. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157.
Cell experiment: | BCECs are seeded in 96-well plates in 200 μL of DMEM medium to obtain a concentration of 2000 cells per well, and incubated for 24 h. The medium in each well is then incubated for 72 h with 200 μL medium containing blank vehicle, P-LPs/ZL006, T7-P-LPs/ZL006 and ZL006 (free drug dissolved in DMSO) with a series of concentrations ranging from 0.001 to 100 μg/mL. The MTT absorbance at 570 nm of each well is measured by a microplate reader. |
Animal experiment: | ICR mice weighting 20 ± 2 g are divided into three groups at random (n=12). Free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 (all containing ZL006 4 mg/kg) are administered to each group through intravenous route, respectively. At designated time intervals (0.5, 1 and 2 h), the mice are executed and the major organs samples including brain, heart, liver, spleen, lung and kidney are collected. Before pretreatment, these tissues are rinsed with cold saline solution to remove the blood and then blotted with paper towel. Protein precipitation of the samples is performed before analysis. Then the samples are injected into the LC-MS/MS systems for analysis. The LC-MS/MS system consists of an Agilent Series 1200 HPLC system and a 6410 Triple Quad LC/MS mass spectrometer. The data is collected and processed using the Agilent MassHunter Workstation Software. |
References: [1]. Wang Z, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015 Jul 29;5:12651. | |
| Cas No. | 1181226-02-7 | SDF | |
| Canonical SMILES | O=C(O)C1=CC=C(NCC2=CC(Cl)=CC(Cl)=C2O)C=C1O | ||
| Formula | C14H11Cl2NO4 | M.Wt | 328.15 |
| Solubility | DMSO : ≥ 29 mg/mL (88.37 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0474 mL | 15.2369 mL | 30.4739 mL |
| 5 mM | 609.5 μL | 3.0474 mL | 6.0948 mL |
| 10 mM | 304.7 μL | 1.5237 mL | 3.0474 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)